spironolactone has been researched along with simvastatin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Calès, P; Feldmann, G; Gallois, Y; Girault, A; le Bouil, A; Le Jeune, JJ; Maïga, MY; Moreau, A; Oberti, F; Pilette, C; Rifflet, H; Saumet, JL | 1 |
| Kunes, J; L'upták, I; Matúsková, J; Pechánová, O; Simko, F; Török, J; Zicha, J | 1 |
| Adamcova, M; Bednarova, K; Krajcirovicova, K; Mullerova, M; Paulis, L; Pechanova, O; Pelouch, V; Simko, F | 1 |
| Adamcova, M; Krajcirovicova, K; Matuskova, J; Paulis, L; Pechanova, O; Pelouch, V; Simko, F | 1 |
| Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE | 1 |
| Hao, SL; Meng, XY; Zhang, CL | 1 |
2 review(s) available for spironolactone and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis.
Topics: Atorvastatin; Female; Humans; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Simvastatin; Spironolactone; Testosterone | 2023 |
14 other study(ies) available for spironolactone and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Topics: Animals; Bile Ducts; Blood Pressure; Double-Blind Method; Hemodynamics; Hypertension, Portal; Hypolipidemic Agents; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Pentoxifylline; Portal Vein; Portasystemic Shunt, Surgical; Rats; Rats, Sprague-Dawley; Reference Values; Renal Circulation; Simvastatin; Spironolactone; Vascular Resistance | 1997 |
Comparison of the effect of simvastatin, spironolactone and L-arginine on endothelial function of aorta in hereditary hypertriglyceridemic rats.
Topics: Acetylcholine; Animals; Aorta; Arginine; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Norepinephrine; Rats; Rats, Wistar; Simvastatin; Spironolactone; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2007 |
Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Captopril; Hypertrophy, Left Ventricular; Kidney; Male; Melatonin; Mineralocorticoid Receptor Antagonists; NF-kappa B; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Simvastatin; Spironolactone; Ventricular Remodeling | 2009 |
Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Wistar; Simvastatin; Spironolactone; Ventricular Remodeling | 2015 |
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid | 2022 |